- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05980598
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)
BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years.
This trial contains a safety run-in to evaluate the safety and tolerability of the two treatment arms: Arm A (TransCon TLR7/8 Agonist plus pembrolizumab) and Arm B (TransCon TLR7/8 Agonist plus TransCon IL-2 β/γ). The safety run-in will be followed by the randomized Phase 2, open-label part of the trial comparing the safety, efficacy and survival of treatment Arm A or Arm B compared to treatment Arm C (pembrolizumab monotherapy).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, Phase 2, open-label, multicenter trial of TransCon TLR7/8 Agonist in combination with pembrolizumab, TransCon TLR7/8 Agonist in combination with TransCon IL-2 β/γ, or pembrolizumab monotherapy as neoadjuvant therapy in participants with Stage III-IVA resectable LA-HNSCC.
This trial starts with a safety run-in of 12 participants, 6 participants each in Arms A (TransCon TLR7/8 Agonist plus pembrolizumab) and B (TransCon TLR7/8 Agonist plus TransCon IL-2 β/γ) randomized 1:1.
After completing the safety run-in, 80 participants will be randomized in a 2:2:1 ratio in 3 treatment Arms A, B or C (pembrolizumab monotherapy).
Once randomized, participants should begin treatment within 5 calendar days. Participants enrolled after the safety run-in, into the 2:2:1 randomization part of the trial, will be stratified as follows: oropharyngeal HPV p16 positive versus oropharyngeal HPV p16 negative or larynx/hypopharyngeal/oral cavity regardless of HPV p16 status. All participants should receive study drug(s) every 21 days (Q21D) for 2 cycles followed by curative-intent surgery. After surgery, participants may receive standard-of-care treatment in the adjuvant setting, as per investigator's decision and local guidelines.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Janet Connolly-Giva
- Phone Number: +1 (650) 512-2153
- Email: jcgt@ascendispharma.com
Study Locations
-
-
-
Tbilisi, Georgia, 0114
- Recruiting
- Ascendis Investigational Site
-
Tbilisi, Georgia, 0159
- Recruiting
- Ascendis Investigational Site
-
Tbilisi, Georgia, 0159
- Recruiting
- Ascendis Investigational Site II
-
Tbilisi, Georgia, 0186
- Recruiting
- Ascendis Investigational Site
-
Tbilisi, Georgia, 0144
- Recruiting
- Ascendis Investigational Site
-
-
Imereti
-
Kutaisi, Imereti, Georgia, 4600
- Recruiting
- Ascendis Investigational Site
-
-
-
-
-
Mannheim, Germany, 68167
- Recruiting
- Ascendis Investigational Site
-
-
Bavaria
-
Erlangen, Bavaria, Germany, 91054
- Recruiting
- Ascendis Investigational Site
-
-
-
-
-
Debrecen, Hungary, 4032
- Recruiting
- Ascendis Investigational Site
-
-
Baranya
-
Pécs, Baranya, Hungary, 7624
- Recruiting
- Ascendis Investigational Site
-
-
-
-
FC
-
Meldola, FC, Italy, 47014
- Recruiting
- Ascendis Investigational Site
-
-
-
-
-
Barcelona, Spain, 08003
- Recruiting
- Ascendis Investigational Site
-
Madrid, Spain, 28040
- Recruiting
- Ascendis Investigational Site
-
Madrid, Spain, 28027
- Recruiting
- Ascendis Investigational Site
-
Málaga, Spain, 29011
- Recruiting
- Ascendis Investigational Site
-
Pamplona, Spain, 31008
- Recruiting
- Ascendis Investigational Site
-
Terrassa, Spain, 08221
- Recruiting
- Ascendis Investigational Site
-
-
-
-
California
-
Los Angeles, California, United States, 90067
- Recruiting
- Ascendis Investigational Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Ascendis Investigational Site
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Ascendis Pharma Investigational Site
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- Ascendis Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37902
- Recruiting
- Ascendis Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has local histologically confirmed new diagnosis of resectable, non-metastatic, SCC that is either: Stage III tumor HPV-positive oropharyngeal primary that is tumor size (T) 4, lymph node involvement (N) 0-2, no distant metastases (M) 0; Stage III or IVA oropharyngeal tumor HPV-negative; or Stage III or IVA larynx/hypopharynx/oral cavity primaries regardless of HPV status (per American Joint Committee on Cancer [AJCC] Staging, 8th edition).
- Has available archived or fresh core or excisional biopsy of a tumor lesion. Note: Fine needle aspirations may be allowed after discussion with Medical Monitor.
- Is eligible and plans for primary LA-HNSCC surgery based on investigator decision and per local practice.
- Has results from tumor HPV status by p16 immunohistochemistry (IHC) for oropharyngeal tumors. (HPV DNA analysis for HPV tumor status is acceptable if that is the local standard of care analysis.)
- Has adequate organ function at screening.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Has at least one lesion that is deemed by the investigator to be easily and safely accessible for IT injection.
Exclusion Criteria:
- Active autoimmune conditions.
- Has significant cardiac disease.
- Has a known bleeding disorder that is deemed to place the participant at unacceptable risk for bleeding complications from IT injections or biopsies.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TransCon TLR7/8 Agonist in combination with pembrolizumab
Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist intratumoral (IT) injection in combination with pembrolizumab as a 30-minute intravenous (IV) infusion
|
TLR7/8 agonist prodrug
A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
Other Names:
|
Experimental: TransCon TLR7/8 Agonist in combination with TransCon IL-2 β/γ
Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist (IT injection) in combination with TransCon IL-2 β/γ as a 30-minute IV infusion
|
TLR7/8 agonist prodrug
Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
|
Active Comparator: Pembrolizumab
Participants receive 2 cycles, once every 3 weeks of pembrolizumab alone as a 30-minute IV infusion
|
A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Pathological Response
Time Frame: Up to 6 weeks after Cycle 2 (each cycle is 21 days)
|
The proportion of participants with a major pathological response (mPR) as assessed by the Central Pathologist at the time of definitive surgery.
mPR is defined as ≤10% invasive squamous cell carcinoma within the resected primary tumor specimen and all the sampled regional lymph nodes.
|
Up to 6 weeks after Cycle 2 (each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Complete Response
Time Frame: Up to 6 weeks after Cycle 2 (each cycle is 21 days)
|
A central pathology laboratory and local hospital pathologist will evaluate if all the tumor is completely gone from the primary tumor and all the lymph nodes that were removed at surgery.
|
Up to 6 weeks after Cycle 2 (each cycle is 21 days)
|
Event Free Survival
Time Frame: Up to 5 years
|
The time from the date of randomization to the date of first record of any of the following events: disease progression; local or distant recurrence determined by radiology scans or tumor biopsy as needed, or death due to any cause.
|
Up to 5 years
|
Overall Survival
Time Frame: Up to 5 years
|
The time from randomization to death due to any cause.
|
Up to 5 years
|
Safety and Tolerability
Time Frame: From time of signing of the ICF up to 100 (±7) days following the last dose of study drug
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
|
From time of signing of the ICF up to 100 (±7) days following the last dose of study drug
|
Collaborators and Investigators
Investigators
- Study Director: Joan Morris, Ascendis Pharma Oncology Division A/S
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- ASND0038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Thomas Jefferson UniversityCompletedHead and Neck CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
Clinical Trials on TransCon TLR7/8 Agonist
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
Global Health Drug Discovery InstituteCMAX Clinical Research Pty Limited; Avance ClinicalCompleted
-
Washington University School of MedicineCompleted
-
University of WashingtonNational Cancer Institute (NCI)CompletedTongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Sheba Medical CenterUnknownEmbryo Transfer | Luteal SupportIsrael
-
Rambam Health Care CampusCompleted
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedRecurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Breast Cancer | Recurrent Breast Carcinoma | Recurrent Colorectal Carcinoma | Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMycosis Fungoides | Recurrent Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Enteropathy-Associated... and other conditionsUnited States